Patexia Logo
Patexia Logo
Products
  • IP Intelligence Reports
  • Patexia Concierge
  • Patent Analyzer
  • Trademarks Analyzer
  • Litigation Analyzer
  • All Products
Services
  • Lateral Opportunities
  • Expert Witness
  • Research Studies
  • Strategic Partnership
  • All Services
IP Community
  • IP Community
  • IP Webinars
  • In the News
Company
  • About Us
  • Press Release
  • Careers
  • Contact Us
Login
JoinBook a Meeting
Company
  • About Us
  • Press Release
  • Careers
  • Contact Us
Products
  • IP Intelligence Reports
  • Patexia Concierge
  • Patent Analyzer
  • Trademarks Analyzer
  • Litigation Analyzer
Services
  • Lateral Opportunities
  • Expert Witness
  • Research Studies
  • Strategic Partnership
Resources
  • IP Community
  • IP Webinars
  • In the News
  • Help Center
Contact
  • (310) 909-7611
  • 100 Wilshire Blvd. Suite 700
    Santa Monica, CA 90401 USA
  • info@patexia.com
  • Contact Us
Follow Us
© 2025
100 Wilshire Blvd, Suite 700, Santa Monica, CA 90401 USA
Terms and Conditions|Privacy Policy
Back to All Articles
Browse articles with tag: Drugs
You must be logged in to create a new article
All Articles
Mikele Bicolli
Jan 13, 2025
•
Featured
ANDA Litigation
Intra-Cellular Therapies Surges 15% Following Settlement of Caplyta ANDA Litigation with Sandoz
Shares of Intra-Cellular Therapies (NASDAQ: ITCI) increased by nearly 15% last week after the company reached a significant settlement with... Read More
Pedram Sameni
Jul 25, 2024
•
ANDA Litigation
Patexia Insight 213: The Revlimid Dispute From Antitrust Battles to Patent Litigation
Revlimid (lenalidomide), developed by Celgene Corporation, has been a groundbreaking treatment for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma... Read More
Mikele Bicolli
Mar 1, 2024
•
Featured
ANDA Litigation
UroGen Pharma Faces Paragraph IV Challenge as Teva Pursues Generic Jelmyto Approval
Shares of UroGen Pharma (NASDAQ: URGN) took a minor premarket hit following news that Teva Pharmaceutical (NYSE: TEVA) has submitted... Read More
Mikele Bicolli
Jan 2, 2024
•
Featured
ANDA Litigation
Corcept Therapeutics Faces Share Price Plunge After Losing Teva Patent Battle
  Corcept Therapeutics experienced a significant drop in its stock value by 27% on Tuesday following an unfavorable verdict in... Read More
Mikele Bicolli
Dec 28, 2023
•
Featured
ANDA Litigation
Pharmaceutical Patents Set to Expire in 2024: Implications and Opportunities
Source: https://www.greyb.com/blog/drug-patents-expiring-2024/   The pharmaceutical industry is undergoing a important phase as numerous patents for key drugs are slated to expire... Read More
Mikele Bicolli
Nov 9, 2022
•
Patent Litigation
The U.S. Supreme Court is About to Ultimately Decide Amgen vs Sanofi Antibody Patent Case
Most of the community involved in life science litigation and pharmaceutical companies, thought they saw the end of the long-fought... Read More
  • <
  • 1
  • 2
  • ...
  • 10
  • >